CD274 and glioblastoma: In subcutaneous GBM models, we demonstrate that PD-L1–FcBP-LNPs achieved >60% tumor growth inhibition without systemic toxicity, demonstrating both potent efficacy and clinical translation potential for precision oncology applications.